Juventas Therapeutics


Juventas Therapeutics is a privately held biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. The company’s lead product, Stromal–cell Derived Factor 1 (SDF–1), has been shown to protect and repair tissue following organ–damage in a broad range of pre–clinical disease models. Juventas is currently initiating a number of clinical studies to test therapy efficiency in different diseases.


Date Type Amount Investors Valuation
07/01/12 Series B 22.2M Triathlon Medical Venture Partners, New Science Ventures, Fletcher Spaght Ventures, Reservoir Venture Partners, Early Stage Partners Unknown